Evidence map›Paper›PMID 18234462›Full record

ArticleMagnetic resonance imaging2008

The detection limit of a Gd3+-based T1 agent is substantially reduced when targeted to a protein microdomain.

Kenjiro Hanaoka, Angelo Josue M Lubag, Aminta Castillo-Muzquiz, Thomas Kodadek, A Dean Sherry

Open access · greenAbstract read
In one paragraph

Article in Magnetic resonance imaging, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Review
  3. MRI Contrast Agents in Glycobiology.Molecules (Basel, Switzerland) · 2022
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Noninvasive MRI of β-cell function using a Zn2+-responsive contrast agent.Proceedings of the National Academy of Sciences of the United States of America · 2011
    Article
  13. Reporter protein-targeted probes for magnetic resonance imaging.Journal of the American Chemical Society · 2011
    Article
  14. Article
  15. Review
  16. Article
  17. A new gadolinium-based MRI zinc sensor.Journal of the American Chemical Society · 2009
    Article
  18. Responsive MRI agents for sensing metabolism in vivo.Accounts of chemical research · 2009
    Review
  19. Molecular imaging without radiopharmaceuticals?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2009
    Article
  20. Polymeric PARACEST agents for enhancing MRI contrast sensitivity.Journal of the American Chemical Society · 2008
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Kenjiro HanaokaDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-9185, USA.
Angelo Josue M Lubag
Aminta Castillo-Muzquiz
Thomas Kodadek
A Dean Sherry
The University of Texas at Dallas · USThe University of Texas Southwestern Medical Center · USSouthwestern Medical Center · US

Funding

TARGETED RESPONSIVE MR AND PET AGENTS FOR B-CELL IMAGINGP01DK058398 · NIDDK · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI MUOIO, DEBORAH M · 2000 to 2016
$26.1M
YTTRIUM HYPERPOLARIZATIONP41RR002584 · NCRR · UT SOUTHWESTERN MEDICAL CENTER · PI MASON, RALPH P. · 1985 to 2011
$14.3M
PARACEST AGENTS FOR MOLECULAR IMAGING OF CANCER BY MRIR01CA115531 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SHERRY, DEAN · 2005 to 2021
$4.2M
NCI NIH HHS CA-115531NCI NIH HHS R01 CA115531NCRR NIH HHS P41 RR002584NCRR NIH HHS RR-02584NIDDK NIH HHS DK-058398NIDDK NIH HHS P01 DK058398
6 · The paper itself

Abstract

Simple low molecular weight (MW) chelates of Gd(3+) such as those currently used in clinical MRI are considered too insensitive for most molecular imaging applications. Here, we evaluated the detection limit (DL) of a molecularly targeted low MW Gd(3+)-based T(1) agent in a model where the receptor concentration was precisely known. The data demonstrate that receptors clustered together to form a microdomain of high local concentration can be imaged successfully even when the bulk concentration of the receptor is quite low. A GdDO3A-peptide identified by phage display to target the anti-FLAG antibody was synthesized, purified and characterized. T(1-)weighted MR images were compared with the agent bound to antibody in bulk solution and with the agent bound to the antibody localized on agarose beads. Fluorescence competition binding assays show that the agent has a high binding affinity (K(D)=150 nM) for the antibody, while the fully bound relaxivity of the GdDO3A-peptide/anti-FLAG antibody in solution was a relatively modest 17 mM(-1) s(-1). The agent/antibody complex was MR silent at concentrations below approximately 9 microM but was detectable down to 4 microM bulk concentrations when presented to antibody clustered together on the surface of agarose beads. These results provided an estimate of the DLs for other T(1)-based agents with higher fully bound relaxivities or multimeric structures bound to clustered receptor molecules. The results demonstrate that the sensitivity of molecularly targeted contrast agents depends on the local microdomain concentration of the target protein and the molecular relaxivity of the bound complex. A model is presented, which predicts that for a molecularly targeted agent consisting of a single Gd(3+) complex with bound relaxivity of 100 mM(-1) s(-1) or, more reasonably, four tethered Gd(3+) complexes each having a bound relaxivity of 25 mM(-1) s(-1), the DL of a protein microdomain is approximately 690 nM at 9.4 T. These experimental and extrapolated DLs are both well below current literature estimates and suggests that detection of low MW molecularly targeted T(1) agents is not an unrealistic goal.

Indexed as

Magnetic Resonance ImagingContrast MediaHeterocyclic CompoundsHeterocyclic Compounds, 1-RingHumansMolecular StructureMolecular WeightOligopeptidesOrganometallic CompoundsPeptidesSuccinimides1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidContrast MediaDOTA-NHSFLAG peptidegadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetateHeterocyclic CompoundsHeterocyclic Compounds, 1-RingOligopeptidesOrganometallic CompoundsPeptidesSuccinimides

Identifiers

PMID18234462
PMCPMC2483407
OpenAlexW2108677671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.